Your Article Summary
See Latest ArticlesSirion Therapeutics Merges With Sytera to Develop New Treatments For Eye Disease
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/17/06
Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced that it has completed a merger with Sytera, Inc., a biopharmaceutical firm based in La Jolla, California committed to discovering new treatments for dry AMD (age- related macular degeneration). The announcement was made jointly by Sirion President and CEO Barry Butler, and Sytera Chairman and CEO Kenneth J. Widder, M.D. The financial terms were not disclosed
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology
b3c newswire, 12/09/09
Federal Advisory Committees to Meet
HealthDataManagement, 12/09/09
Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR
Mylan, 12/09/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
New study results presented at 2009 san antonio breast cancer symposium show importance of protecting your bones
Amgen, 12/11/09
Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, 12/11/09